Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma

Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial

Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility

Glenmark Pharmaceuticals Announces Launch of Nebzmart^® GFB Smartules® and Glenmark Airz® FB Smartules®, World’s First Nebulized Triple Therapy for COPD

Cosmo and Glenmark Announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe

Glenmark Pharmaceuticals Announces Q2FY26 Results

Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership

Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials

Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer

Glenmark to launch Eribulin Mesylate Injection 1 mg-2 mL (0.5 mg-mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)

Glenmark Pharmaceuticals announces Q1FY26 results

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie

Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya

Glenmark Pharmaceuticals Launches TEVIMBRA® in India

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies

Glenmark Pharma Reports Q4 & FY25 Financial results

Glenmark Foundation Leads Combat Against Malnutrition with its Transformative Initiative ‘Meri Poushtik Rasoi’ Season Seven

Glenmark Pharmaceuticals Inc., USA to launch Mixed Amphetamines Immediate-Release Tablets

Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)

Glenmark Nutrition Awards 2025: Celebrating Innovation, Impact, and Sustainability in the Fight Against Malnutrition in India